KEFLET
LOE ApproachingNDAORALTABLET
Approved
Oct 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEFLET is an oral tablet small-molecule NDA approved in 1972 by Eli Lilly and Company. The generic composition and specific indications are not disclosed in available data. It is a legacy product nearing loss of exclusivity.
LOE Approaching
LOE-approaching product with moderate competitive pressure (30/100) suggests a contracting brand team focused on generic transition planning and niche market retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
No active job postings are linked to KEFLET, reflecting its legacy status and minimal staffing needs. Working on this product offers limited career growth but valuable experience in generic transition, compliance, and declining-asset portfolio management.
Brand ManagerGeneric Strategy Lead
Worked on KEFLET at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.